Är Siegfried Holding utdelningen säker?
Siegfried Holding har höjt utdelningen i 8 år.
Inom de senaste 10 åren har Siegfried Holding ökat denna med årligen 10,976 % ökad.
På 5-årssikt ökade utdelningen med 7,215 %.
Analytikerna räknar med en Utdelningsökning på 8,268% för det löpande räkenskapsåret.
Siegfried Holding Aktienanalyse
Vad gör Siegfried Holding?
The Siegfried Holding AG is a Swiss pharmaceutical company based in Zofingen, which operates worldwide. The company's history dates back to 1873, when the pharmacist and chemist Franz von Siegfried founded the "First Aid Pharmacy". Over the years, the company has developed into an important producer of pharmaceutical ingredients.
The business model of Siegfried Holding AG is based on the production and distribution of pharmaceutical ingredients, intermediate products, and finished products. The products are used in various areas, such as veterinary medicine, human medicine, or the chemical industry.
Siegfried operates various divisions that focus on different segments of the value chain. These divisions include production, contract development and manufacturing (CDMO), and commercial products. In the production division, the company produces pharmaceutical ingredients and intermediate products. The CDMO business offers custom development and manufacturing services for the pharmaceutical and biotech industry. In the commercial products division, finished products such as cough medicine, antidepressants, or blood pressure reducers are distributed.
Among the products offered by Siegfried are the active ingredient carbamazepine, which is used as an anticonvulsant and for the treatment of bipolar disorder. Another active ingredient is acetaminophen, which is used as a painkiller and fever reducer. Siegfried also produces the active ingredient sotalol, which is used to treat heart rhythm disorders.
In the context of the CDMO business, Siegfried also develops and produces custom products for the pharmaceutical and biotech industry. This includes the manufacturing of clinical trial preparations, the implementation of process developments, and scale-up productions of active ingredients and finished products.
In recent years, Siegfried Holding AG has made several acquisitions to expand its business and strengthen its market presence. In 2016, the company acquired Bexbach-based Saltigo GmbH, a specialist in the production of customer-specific fine chemicals. Two years later, Siegfried acquired the active ingredient production business of Alcami, a US pharmaceutical company.
In summary, it can be said that Siegfried Holding AG is an established Swiss pharmaceutical company specializing in the production and distribution of pharmaceutical ingredients, intermediate products, and finished products. In recent years, the company has made several acquisitions to expand its market presence and diversify its business. Siegfried Holding är ett av de mest populära företagen på Eulerpool.com.Aktiesparprogram erbjuder en attraktiv möjlighet för investerare att bygga upp ett långsiktigt kapital. En av huvudfördelarna är den så kallade kostnadsgenomsnittseffekten: Genom att regelbundet investera en fast summa i aktier eller aktiefonder, köper man automatiskt fler andelar när priserna är låga, och färre när de är höga. Detta kan leda till ett mer fördelaktigt genomsnittspris per andel över tid. Dessutom möjliggör aktiesparprogram även för småsparare att få tillgång till dyra aktier, eftersom de kan delta med små summor. Den regelbundna investeringen främjar också en disciplinerad investeringsstrategi och hjälper till att undvika emotionella beslut, som impulsivt köpande eller säljande. Utöver detta, drar investerare nytta av den potentiella värdetillväxten i aktierna såväl som från utdelningar som kan återinvesteras, vilket förstärker ränta-på-ränta-effekten och således tillväxten av det investerade kapitalet.